KZIA Earnings Date: Nov 6, 2026 (Estimated) — Kazia Therapeutics Ltd ADR
NASDAQ · Healthcare · Biotechnology
Updated
When is KZIA's next earnings date?
Kazia Therapeutics Ltd ADR (KZIA) is expected to report FY 2026 earnings on Friday, November 6, 2026 at 9:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.01 on revenue of $60,000.
How did KZIA do in its last earnings report?
In its most recent report on Sep 4, 2026, Kazia Therapeutics Ltd ADR posted EPS of -$0.60 versus the -$0.61 estimate, a beat of 0.9%. Revenue was $183,383 against a $488,858 estimate. The stock's 1-day post-earnings move was -1.2%.
How much does KZIA stock move after earnings?
KZIA beat EPS estimates in 1 of its last 2 reported quarters. Over the last 5 reports the stock moved an average of 4.2% (up or down) in the day after earnings.
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-04 | -0.61 | -0.60 | +0.89% | $183,383 | ✅ Beat | -1.23% | -7.98% | -23.11% | |
| 2024-11-15 | FY 2024 | — | -0.07 | — | $15.6M | — | -13.28% | +4.93% | -36.81% |
| 2024-03-27 | H1 2024 | — | -0.02 | — | $4,205 | — | -0.63% | +6.72% | +17.17% |
| 2023-09-05 | FY 2023 | — | -0.08 | — | $15,562 | — | +4.12% | +9.28% | -5.15% |
| 2023-03-07 | H1 2023 | — | -0.06 | — | $93,188 | — | +1.84% | -2.97% | +8.91% |
| 2022-10-06 | -29.93 | -30.53 | — | — | ❌ Miss | — | — | — | |
| 2022-02-22 | — | -35.72 | — | $18,072 | — | — | — | — | |
| 2021-09-30 | — | -5.86 | — | $11.4M | — | — | — | — |
Showing last 8 quarters.